Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose-Escalation and Multiple Cohort Dose Expansion Phase 1b Clinical Trial

NCT06963814 is registered in ClinicalTrials.gov with HC Biopharma Inc. as lead sponsor.

NCT NCT06963814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06963814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose-Escalation and Multiple Cohort Dose Expansion Phase 1b Clinical Trial
Lead sponsor
HC Biopharma Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 4, 2025
Completion date
May 30, 2027
Enrollment
252 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer